Williams-Sonoma, Inc. WSM saw several analysts reiterate their coverage, with one analyst making a modest reduction to the price forecast following Thursday's first-quarter results.

A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. NYSE: PFE certainly catches the eye of income-seeking investors.

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE:ELV) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc.

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BigBear.ai Holdings, Inc. (NYSE:BBAI) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in BigBear.ai, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bigbearai-holdings-inc.

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Civitas Resources, Inc. (NYSE:CIVI) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Civitas you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/civitas-resources-inc.

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Diversified Holdings and Compass Group Diversified Holdings, LLC (NYSE:CODI) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Compass you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/compass-diversified-holdings.

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc.

BioHarvest Sciences Inc. (NASDAQ:BHST) earlier this week announced a new contract targeting the plant-based fragrance compound market, using its proprietary botanical synthesis platform. CEO Ilan Sobel said the contract focuses on a rare plant under threat from overharvesting and habitat loss.

IonQ, Inc.'s new CEO aspires to make the company the "Nvidia of quantum computing," but current fundamentals don't justify such lofty valuations. The company quietly hiked the projected 2025 adjusted EBITDA loss by 35%, without a corresponding rise in revenue guidance. IonQ made 2 acquisitions, quietly issuing over 24 million shares valued at $1.2 billion.

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / WHY: New York, N.Y., May 23, 2025.

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Compass Group Diversified Holdings, LLC (NYSE:CODI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/compass-diversified-lawsuit-submission-form?prid=150020&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.

Apple Inc. faces a potential 25% tariff on iPhones made outside the U.S., directly threatened by President Trump. The company's shift to India and Vietnam was meant to reduce China risk, but it's now clashing with U.S. political pressure. Building iPhones in the U.S. is economically unviable in the short term, and absorbing tariffs or raising prices would severely hurt margins or demand.

I remain cautiously optimistic about Agenus, driven by BOT/BAL's strong clinical data and cost-reduction efforts, but maintain a speculative 2/5 conviction rating. The BOT/BAL program shows promising efficacy in MSS colorectal cancer, potentially resetting the standard of care and offering a significant commercial opportunity. Agenus's restructuring, asset monetization, and cost cuts aim to extend the runway and avoid near-term dilution, but financial risks and execution remain key concerns.

CNBC's Eamon Javers reports on the latest conversations from inside the Oval Office.

Daniel Newman, The Futurum Group CEO, and James Cakmak, Clockwise Capital CIO, join 'Power Lunch' to discuss Trump's tariff threats on Apple, if the market reaction is overdone and much more.

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Digimarc Corporation (NASDAQ: DMRC) between May 3, 2024 and February 26, 2025, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline.

Accenture plc's recent price correction is an overreaction to a few temporary macroeconomic headwinds. These headwinds include the DOGE initiatives and trade disputes, but are temporary in my view. Fundamentally, I see a highly profitable business with promising growth potential (especially AI-related) at a discounted price.

A handful of stocks benefited massively during the pandemic. It was an interesting time to be an investor, to say the least, and those who targeted the stay-at-home stocks were rewarded handsomely with considerable gains.

"The less we're talking about tariffs, the more optimistic I am," argues Jed Ellerbroek. He sees promise in A.I.